151P A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumabM. Persano, Fabian Finkelmeier, G. Giordano et al.|Annals of Oncology|2024Cited by 0
77P A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumabM. Persano, A. Casadei Gardini, Lorenzo Fornaro et al.|Immuno-Oncology Technology|2024Cited by 0
106P Impact of molecular alterations in advanced biliary tract cancer (BTC) patients (pts) treated with cisplatin, gemcitabine, durvalumab (CGD): A large global studyF. Lo Prinzi, A. Casadei Gardini, M. Rimini et al.|ESMO Open|2025Cited by 0
109P Prognostic impact of target-directed therapies in biliary tract cancer patients harboring molecular alterationsSilvia Camera, A. Casadei-Gardini, M. Rimini et al.|ESMO Open|2025Cited by 0
353P Prognostic role of metastatic sites in a worldwide population of patients with biliary tract cancer treated with cisplatin, gemcitabine, and durvalumabSilvia Camera, Lorenzo Fornaro, M. Rimini et al.|Annals of Oncology|2025Cited by 0